<DOC>
	<DOC>NCT00863538</DOC>
	<brief_summary>To evaluate the efficacy, safety and pharmacokinetics profile of KPS-0373 in patients with SCD</brief_summary>
	<brief_title>Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)</brief_title>
	<detailed_description />
	<mesh_term>Spinocerebellar Degenerations</mesh_term>
	<mesh_term>Spinocerebellar Ataxias</mesh_term>
	<mesh_term>Thyrotropin-Releasing Hormone</mesh_term>
	<criteria>SCD with mild to moderate ataxia Patients with secondary ataxia Patients with clinically significant hepatic, renal, or cardiovascular dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Spinocerebellar degeneration</keyword>
	<keyword>Thyrotropin-Releasing Hormone (TRH)</keyword>
	<keyword>SCD</keyword>
</DOC>